130 related articles for article (PubMed ID: 16937357)
41. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J
Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308
[TBL] [Abstract][Full Text] [Related]
42. Hypermethylation of the p16 gene and lack of p16 expression in hepatoblastoma.
Shim YH; Park HJ; Choi MS; Kim JS; Kim H; Kim JJ; Jang JJ; Yu E
Mod Pathol; 2003 May; 16(5):430-6. PubMed ID: 12748249
[TBL] [Abstract][Full Text] [Related]
43. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
[TBL] [Abstract][Full Text] [Related]
44. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis.
Wang J; Wang B; Chen X; Bi J
Carcinogenesis; 2011 Mar; 32(3):411-6. PubMed ID: 21156971
[TBL] [Abstract][Full Text] [Related]
45. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
46. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
[TBL] [Abstract][Full Text] [Related]
47. Epigenetic inactivation of RASSF1a in uveal melanoma.
Maat W; van der Velden PA; Out-Luiting C; Plug M; Dirks-Mulder A; Jager MJ; Gruis NA
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):486-90. PubMed ID: 17251440
[TBL] [Abstract][Full Text] [Related]
48. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
[TBL] [Abstract][Full Text] [Related]
49. DNA methylation patterns of RAR-β2 and RASSF1A gene promoters in FNAB samples from Greek population with benign or malignant breast lesions.
Kougioumtsidou N; Vavoulidis E; Nasioutziki M; Symeonidou M; Pratilas GC; Mareti E; Petousis S; Chatzikyriakidou A; Grimbizis G; Theodoridis T; Miliaras D; Dinas K; Zepiridis L
Diagn Cytopathol; 2021 Jan; 49(1):153-164. PubMed ID: 32530576
[TBL] [Abstract][Full Text] [Related]
50. Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients.
Rasti M; Tavasoli P; Monabati A; Entezam M
Iran Biomed J; 2009 Oct; 13(4):199-206. PubMed ID: 19946345
[TBL] [Abstract][Full Text] [Related]
51. Genetic and epigenetic alterations of the EGFR and mutually independent association with BRCA1, MGMT, and RASSF1A methylations in Vietnamese lung adenocarcinomas.
Nguyen QN; Vuong LD; Truong VL; Ta TV; Nguyen NT; Nguyen HP; Chu HH
Pathol Res Pract; 2019 May; 215(5):885-892. PubMed ID: 30723053
[TBL] [Abstract][Full Text] [Related]
52. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
[TBL] [Abstract][Full Text] [Related]
53. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma.
Park WS; Oh RR; Park JY; Kim PJ; Shin MS; Lee JH; Kim HS; Lee SH; Kim SY; Park YG; An WG; Kim HS; Jang JJ; Yoo NJ; Lee JY
J Pathol; 2001 Apr; 193(4):483-90. PubMed ID: 11276007
[TBL] [Abstract][Full Text] [Related]
54. Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver.
Di Gioia S; Bianchi P; Destro A; Grizzi F; Malesci A; Laghi L; Levrero M; Morabito A; Roncalli M
BMC Cancer; 2006 Apr; 6():89. PubMed ID: 16606445
[TBL] [Abstract][Full Text] [Related]
55. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling.
Lindsey JC; Lusher ME; Anderton JA; Bailey S; Gilbertson RJ; Pearson AD; Ellison DW; Clifford SC
Carcinogenesis; 2004 May; 25(5):661-8. PubMed ID: 14688019
[TBL] [Abstract][Full Text] [Related]
56. WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors.
Pannone G; Bufo P; Santoro A; Franco R; Aquino G; Longo F; Botti G; Serpico R; Cafarelli B; Abbruzzese A; Caraglia M; Papagerakis S; Lo Muzio L
Oncol Rep; 2010 Oct; 24(4):1035-41. PubMed ID: 20811686
[TBL] [Abstract][Full Text] [Related]
57. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
58. Methylation status of SFRP1, SFRP2, RASSF1A, RARβ and DAPK1 genes in patients with oral squamous cell carcinoma.
Strzelczyk JK; Krakowczyk Ł; Owczarek AJ
Arch Oral Biol; 2019 Feb; 98():265-272. PubMed ID: 30576962
[TBL] [Abstract][Full Text] [Related]
59. DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinoma.
Lin JC; Wu YC; Wu CC; Shih PY; Wang WY; Chien YC
Ann Hepatol; 2015; 14(4):494-504. PubMed ID: 26019036
[TBL] [Abstract][Full Text] [Related]
60. Methylation analysis of SFRP genes family in cervical adenocarcinoma.
Lin YW; Chung MT; Lai HC; De Yan M; Shih YL; Chang CC; Yu MH
J Cancer Res Clin Oncol; 2009 Dec; 135(12):1665-74. PubMed ID: 19513747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
